Overview

Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is the first clinical trial using sodium oxybate for the treatment of REM sleep behavior disorder (RBD). Sodium oxybate is a drug approved by FDA for the treatment of narcolepsy which has been used "off label" to treat patients with severe RBD. This drug has shown to be effective and well tolerated in patients with RBD (Shneerson, 2009; Liebenthal, 2016; Moghadam, 2017).
Phase:
Phase 4
Details
Lead Sponsor:
Stanford University
Collaborator:
Jazz Pharmaceuticals
Treatments:
Sodium Oxybate